TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T19531	Adenylate cyclase type 5	B0EX2T	[[(1S,4R)-4-(6-Amino-9H-purine-9-yl)-2-cyclopentene-1-yl]oxy]acetic acid	Investigative	44335712	C12H13N5O3	275.26	C1[C@H](C=C[C@H]1OCC(=O)O)N2C=NC3=C(N=CN=C32)N	IC50 = 78000 nM	Poor binder
T19531	Adenylate cyclase type 5	B28SZT	(1S,3R)-2-[3-(6-Amino-purin-9-yl)-cyclopentyl]-N-hydroxy-acetamide	Investigative	11054944	C12H16N6O2	276.29	C1C[C@H](C[C@H]1CC(=O)NO)N2C=NC3=C(N=CN=C32)N	IC50 = 55000 nM	Poor binder
T19531	Adenylate cyclase type 5	B29TSC	(1R,3R)-4-(6-Amino-purin-9-yl)-cyclopent-2-enecarboxylic acid hydroxyamide	Investigative	11097296	C11H12N6O2	260.25	C1[C@@H](C=C[C@H]1N2C=NC3=C(N=CN=C32)N)C(=O)NO	IC50 = 100000 nM	Poor binder
T19531	Adenylate cyclase type 5	B4U6YT	[3-(6-Amino-purin-9-yl)-propoxy]-acetic acid	Investigative	44335335	C10H13N5O3	251.24	C1=NC(=C2C(=N1)N(C=N2)CCCOCC(=O)O)N	IC50 = 140500 nM	Poor binder
T19531	Adenylate cyclase type 5	B4X0FU	(1S,3S)-[3-(6-Amino-purin-9-yl)-cyclopentyl]-acetic acid	Investigative	10934245	C12H15N5O2	261.279	C1C[C@@H](C[C@H]1CC(=O)O)N2C=NC3=C(N=CN=C32)N	IC50 ~ 100000 nM	Poor binder
T19531	Adenylate cyclase type 5	B83EGQ	[[(1R,4S)-4-(6-Amino-9H-purine-9-yl)-2-cyclopentene-1-yl]oxy]acetic acid	Investigative	44335939	C12H13N5O3	275.26	C1[C@@H](C=C[C@@H]1OCC(=O)O)N2C=NC3=C(N=CN=C32)N	IC50 = 98000 nM	Poor binder
T19531	Adenylate cyclase type 5	B8Q7ZX	(1S,3R)-3-(6-Amino-purin-9-yl)-cyclopentanecarboxylic acid hydroxyamide	Investigative	11108129	C11H14N6O2	262.27	C1C[C@H](C[C@H]1C(=O)NO)N2C=NC3=C(N=CN=C32)N	IC50 ~ 70000 nM	Poor binder
T19531	Adenylate cyclase type 5	B9DZV0	(1R,3R)-3-(6-Amino-9H-purin-9-yl)-N-hydroxycyclopentanecarboxamide	Investigative	9834991	C11H14N6O2	262.27	C1C[C@H](C[C@@H]1C(=O)NO)N2C=NC3=C(N=CN=C32)N	IC50 = 78000 nM	Poor binder
T19531	Adenylate cyclase type 5	B9M7TE	2-[[(1S,4R)-4-(6-Amino-9H-purine-9-yl)-2-cyclopentene-1-yl]oxy]acetohydroximic acid	Investigative	44335709	C12H14N6O3	290.28	C1[C@H](C=C[C@H]1OCC(=O)NO)N2C=NC3=C(N=CN=C32)N	IC50 = 116000 nM	Poor binder
T19531	Adenylate cyclase type 5	BBIJ70	2-[(S)-3-((S)-6-Amino-purin-9-yl)-cyclopentyloxy]-N-hydroxy-acetamide	Investigative	44335982	C12H16N6O3	292.29	C1C[C@@H](C[C@@H]1N2C=NC3=C(N=CN=C32)N)OCC(=O)NO	IC50 = 109000 nM	Poor binder
T19531	Adenylate cyclase type 5	BFH91C	[[(1S,4S)-4-(6-Amino-9H-purine-9-yl)-2-cyclopentene-1-yl]oxy]acetic acid	Investigative	44335700	C12H13N5O3	275.26	C1[C@@H](C=C[C@H]1OCC(=O)O)N2C=NC3=C(N=CN=C32)N	IC50 = 72000 nM	Poor binder
T19531	Adenylate cyclase type 5	BFU40K	2-[[(1R,4S)-4-(6-Amino-9H-purine-9-yl)-2-cyclopentene-1-yl]oxy]acetohydroximic acid	Investigative	44335742	C12H14N6O3	290.28	C1[C@@H](C=C[C@@H]1OCC(=O)NO)N2C=NC3=C(N=CN=C32)N	IC50 = 96000 nM	Poor binder
T19531	Adenylate cyclase type 5	BM6T2N	2-[3-(6-Amino-9H-purine-9-yl)propoxy]acetohydroximic acid	Investigative	44335393	C10H14N6O3	266.26	C1=NC(=C2C(=N1)N(C=N2)CCCOCC(=O)NO)N	IC50 = 94000 nM	Poor binder
T19531	Adenylate cyclase type 5	BQB5J6	(1S,3S)-[4-(6-Amino-purin-9-yl)-cyclopent-2-enyl]-acetic acid	Investigative	11780214	C12H13N5O2	259.26	C1[C@H](C=C[C@H]1N2C=NC3=C(N=CN=C32)N)CC(=O)O	IC50 = 73200 nM	Poor binder
T19531	Adenylate cyclase type 5	BRZ65I	[(S)-3-((S)-6-Amino-purin-9-yl)-cyclopentyloxy]-acetic acid	Investigative	44335725	C12H15N5O3	277.28	C1C[C@@H](C[C@@H]1N2C=NC3=C(N=CN=C32)N)OCC(=O)O	IC50 = 79000 nM	Poor binder
T19531	Adenylate cyclase type 5	BWV49J	(1S,3R)-4-(6-Amino-purin-9-yl)-cyclopent-2-enecarboxylic acid hydroxyamide	Investigative	11032616	C11H12N6O2	260.25	C1[C@@H](C=C[C@@H]1N2C=NC3=C(N=CN=C32)N)C(=O)NO	IC50 = 188000 nM	Poor binder
T19531	Adenylate cyclase type 5	BXD1V5	2-[(R)-3-((R)-6-Amino-purin-9-yl)-cyclopentyloxy]-N-hydroxy-acetamide	Investigative	44335701	C12H16N6O3	292.29	C1C[C@H](C[C@H]1N2C=NC3=C(N=CN=C32)N)OCC(=O)NO	IC50 = 110000 nM	Poor binder